<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02514278</url>
  </required_header>
  <id_info>
    <org_study_id>CHUBX 2014/33</org_study_id>
    <nct_id>NCT02514278</nct_id>
  </id_info>
  <brief_title>Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy</brief_title>
  <acronym>GRECCAR12</acronym>
  <official_title>Optimisation of Response for Organ Preservation in Rectal Cancer : Neoadjuvant Chemotherapy and Radiochemotherapy vs. Radiochemotherapy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University Hospital, Bordeaux</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University Hospital, Bordeaux</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Standard treatment of rectal cancer is rectal excision with neoadjuvant radiochemotherapy. A&#xD;
      new concept suggests organ preservation as an alternative to rectal excision in good&#xD;
      responders after neoadjuvant radiochemotherapy to decrease surgical morbidity and increase&#xD;
      quality of life. The rational is the fact that 15% of patients have sterilized tumours after&#xD;
      radiochemotherapy for T3T4 rectal cancer. The French GRECCAR 2 trial is the first phase III&#xD;
      trial investigating this strategy: patients with T2T3 low rectal carcinomas (size ≤4 cm)&#xD;
      received 50 Gy with capecitabine and good clinical responders (≤2 cm) were randomized between&#xD;
      local and rectal excision. The main findings were: the rate of complete pathologic response&#xD;
      was higher after radiochemotherapy for small T2T3 than for T3T4 tumours (40% vs 15% ypT0) and&#xD;
      good pathologic responders (ypT0-1) were associated with zero positive mesorectal nodes.&#xD;
&#xD;
      The objective of the new trial is to increase the proportion of patients treated with organ&#xD;
      preservation by optimizing tumour response. As compared to Folfiri, tritherapy Folfirinox has&#xD;
      been shown to enhance the response rate. In patients with colorectal metastases, response&#xD;
      rate and R0 resection were twice higher, resulting in improved survival. Folfirinox also&#xD;
      increases response and chance of R0 resection rates in initially unresectable colorectal&#xD;
      metastases, compared to standard or intensified bi-chemotherapy regimens. Adding two months&#xD;
      of neoadjuvant chemotherapy (Folfirinox) before radiochemotherapy, the investigators expect&#xD;
      to increase chance of organ preservation rate, as compared to radiochemotherapy alone.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 28, 2016</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2022</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Supportive Care</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of organ preservation and absence of stoma</measure>
    <time_frame>1 year after surgery</time_frame>
    <description>Number of patients with organ preservation and absence of stoma at 1 year after surgery</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Compliance to treatment</measure>
    <time_frame>From beginning of neoadjuvant treatment until surgery, expected average 20 weeks after neoadjuvant treatment</time_frame>
    <description>Number of patients receiving full neoadjuvent treatment and the allocated surgery</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Tolerance to treatment</measure>
    <time_frame>From beginning of neoadjuvant treatment until 1 year after surgery</time_frame>
    <description>Number of patients with adverse events</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of clinical complete response</measure>
    <time_frame>At 8 weeks after neoadjuvant treatment</time_frame>
    <description>To determine the rate of grade 1 : no tumor at digital examination</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of radiological response</measure>
    <time_frame>At 8 weeks after neoadjuvant treatment</time_frame>
    <description>To determine the rate of tumor ≤ 2 cm with TRG1-3 at MRI</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of complete pathologic response</measure>
    <time_frame>At surgery, expected average 10 weeks after neoadjuvant treatment</time_frame>
    <description>To determine the rate of ypT0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between radiological and clinical response</measure>
    <time_frame>Between 8 to 10 weeks after neoadjuvant treatment</time_frame>
    <description>To analyse the correlation between radiological response ( tumor ≤ 2 cm with TRG1-3 at MRI) and clinical response (grade 1)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Correlation between radiological and pathologic response</measure>
    <time_frame>Between 8 to 10 weeks after neoadjuvant treatment</time_frame>
    <description>To analyse the correlation between radiological response ( tumor ≤ 2 cm with TRG1-3 at MRI) and pathological response (ypT0)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of curative surgery</measure>
    <time_frame>At surgery, expected average 10 weeks after neoadjuvant treatment</time_frame>
    <description>To determine the rate of R0 resection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surgical morbidity</measure>
    <time_frame>From surgery until 1 year of follow-up</time_frame>
    <description>To analyse the cumulative Clavien-Dindo at 1 year</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quality of life</measure>
    <time_frame>From randomization until 1 year after surgery</time_frame>
    <description>To examine score of questionnaires : QLQ CR-30, QLQ CR-29</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Local recurrence</measure>
    <time_frame>From surgery until 3 years of follow-up</time_frame>
    <description>To determine the rate of local recurrence at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From surgery until 3 years of follow-up</time_frame>
    <description>To determine the rate of overall survival at 3 years</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease-free survival</measure>
    <time_frame>From surgery until 3 years of follow-up</time_frame>
    <description>To determine the rate of disease-free survival at 3 years</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">218</enrollment>
  <condition>Rectal Cancer</condition>
  <arm_group>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Neoadjuvant chemotherapy Folfirinox, 4 cycles:&#xD;
oxaliplatin: 85 mg/m2&#xD;
irinotecan: 180 mg/m²&#xD;
folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)&#xD;
5FU: 2400 mg/m2&#xD;
Radiochemotherapy : 2 to 4 weeks after chemotherapy, 5 weeks (50 Gy, 2 Gy/session; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Radiochemotherapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Radiochemotherapy: 5 weeks (50 Gy, 2 Gy/session ; 25 fractions) + capecitabine (1600 mg/m2 daily 5 days/7, excluding weekends)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Neoadjuvant chemotherapy Folfirinox, 4 cycles</intervention_name>
    <description>oxaliplatin: 85 mg/m2&#xD;
irinotecan: 180 mg/m²&#xD;
folinic acid: 400 mg/m2 (DL form) or 200 mg/m2 (L form)&#xD;
5FU: 2400 mg/m2</description>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>50 Gy, 2 Gy/session; 25 fractions</intervention_name>
    <description>Radiochemotherapy 5 weeks</description>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
    <arm_group_label>Radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Local excision in good responders</intervention_name>
    <description>If local excision:&#xD;
Surveillance if ypT0-1 or ypT2Nx/cN0 (no lymph node at baseline imaging)&#xD;
Complementary rectal excision if ypT2Nx/cN1, ypT3 or R1.</description>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
    <arm_group_label>Radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Rectal excision in bad responders</intervention_name>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
    <arm_group_label>Radiochemotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Capecitabine</intervention_name>
    <description>1600 mg/m2 daily 5 days/7</description>
    <arm_group_label>Chemotherapy and Radiochemotherapy</arm_group_label>
    <arm_group_label>Radiochemotherapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Rectal adenocarcinoma&#xD;
&#xD;
          -  cT2T3&#xD;
&#xD;
          -  cN0-1 (≤ 3 positive lymph nodes or size ≤8mm)&#xD;
&#xD;
          -  Tumour size ≤4 cm&#xD;
&#xD;
          -  Location ≤10 cm from the anal verge&#xD;
&#xD;
          -  No distant metastasis&#xD;
&#xD;
          -  Patient ≥18 years&#xD;
&#xD;
          -  ECOG ≤2&#xD;
&#xD;
          -  Effective contraception during the study&#xD;
&#xD;
          -  Patient and doctor have signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  T1 or T4&#xD;
&#xD;
          -  Tumour size &gt;4cm&#xD;
&#xD;
          -  N2 (&gt;3 positive lymph nodes or size &gt;8mm)&#xD;
&#xD;
          -  Tumour &gt; 10 cm from the anal verge&#xD;
&#xD;
          -  Distant metastasis&#xD;
&#xD;
          -  Chronic intestinal inflammation and/or bowel obstruction&#xD;
&#xD;
          -  Contra indication for chemotherapy and/or radiotherapy&#xD;
&#xD;
          -  Previous pelvic radiotherapy or chemotherapy&#xD;
&#xD;
          -  Severe renal, hepatic insufficiency (serum creatinine&lt;30ml/min)&#xD;
&#xD;
          -  Peripheral neuropathy &gt; grade 1&#xD;
&#xD;
          -  Complete or partial Dihydropyrimidine deshydrogenase (DPD) deficiency (uracilemia ≥ 16&#xD;
             ng/mL)&#xD;
&#xD;
          -  Concomitant treatment with millepertuis, yellow fever vaccine, phenytoin or sorivudine&#xD;
             (or chemically equivalent)&#xD;
&#xD;
          -  Pregnant or breast-feeding woman.&#xD;
&#xD;
          -  Persons deprived of liberty or under guardianship&#xD;
&#xD;
          -  Impossibility for compliance to follow-up&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric RULLIER, Prof.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University Hospital Bordeaux, France</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU Amiens Picardie</name>
      <address>
        <city>Amiens</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU de Besançon</name>
      <address>
        <city>Besançon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Saint-André - CHU de Bordeaux</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Institut Bergonié</name>
      <address>
        <city>Bordeaux</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU Estaing - CHRU Clermont Ferrand</name>
      <address>
        <city>Clermont-Ferrand</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Beaujon - APHP</name>
      <address>
        <city>Clichy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Centre Georges François Leclerc - Dijon</name>
      <address>
        <city>Dijon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Albert Michallon - CHU de Grenoble</name>
      <address>
        <city>La Tronche</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Centre Oscar Lambret - Lille</name>
      <address>
        <city>Lille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Centre Léon Bérard - Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Lyon Sud - CHU Lyon</name>
      <address>
        <city>Lyon</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU de la Timone - Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Institut Paoli Calmette - Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestives, Hôpital Européen de Marseille</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Institut du Cancer de Montpellier</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service d'Oncologie et Radiothérapie, Centre Azuréen de Cancérologie</name>
      <address>
        <city>Mougins</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive,Institut de Cancérologie de Lorraine</name>
      <address>
        <city>Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôtel Dieu - CHU de Nantes</name>
      <address>
        <city>Nantes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, CHU Carémeau - Nîmes</name>
      <address>
        <city>Nîmes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>GH Paris Saint Joseph</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive et Oncologique, Hôpital Bicêtre - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital les Diaconnesses</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Saint-Antoine - APHP</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Saint-Louis - APHP Paris</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Pontchaillou - CHU Rennes</name>
      <address>
        <city>Rennes</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Charles Nicolle - CHU de Rouen</name>
      <address>
        <city>Rouen</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de Chirurgie Digestive, Hôpital Purpan - CHU de Toulouse</name>
      <address>
        <city>Toulouse</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Service de chirurgie digestive, CHRU de Nancy -Hôpital de Brabois</name>
      <address>
        <city>Vandœuvre-lès-Nancy</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Département de chirurgie digestive, Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>July 6, 2015</study_first_submitted>
  <study_first_submitted_qc>July 31, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 3, 2015</study_first_posted>
  <last_update_submitted>June 8, 2021</last_update_submitted>
  <last_update_submitted_qc>June 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 9, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Organ preservation</keyword>
  <keyword>Local excision</keyword>
  <keyword>Radiochemotherapy</keyword>
  <keyword>Neoadjuvant chemotherapy</keyword>
  <keyword>Folfirinox</keyword>
  <keyword>Tumour response</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Capecitabine</mesh_term>
    <mesh_term>Folfirinox</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

